News

Shares of Reata Pharmaceuticals (NASDAQ: RETA) recently jumped about 54% higher in a single trading session. This biotech stock was already way up this year thanks to the recent approval of its

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for

Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a crucial moment in their stories. The biotech companies are awaiting regulatory decisions for

A high price tag sometimes indicates value, be it in equity markets or elsewhere. Still, excellent stocks can be had for a relatively modest sum. With just $100 or even less, investors can get their

The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are

The stock market has rallied so far this year, particularly in the period between the last earnings season and this one. Companies now have to prove to Wall Street that their higher stock prices are

Animal health company Zoetis (NYSE: ZTS) and pharmaceutical giant Eli Lilly (NYSE: LLY) are healthcare companies that are off to solid starts this year, with Zoetis' shares up more than 30% and

Medtronic (NYSE: MDT) is a top medical device maker that pays a high dividend. With operations in 150 countries with products helping people with more than 70 different health conditions, it has a

Dividend stocks can practically be a retiree's best friend. At least, the right ones can be. Three Motley Fool contributors were asked to identify healthcare dividend stocks they think retirees

Image source: The Motley Fool.

Centene (NYSE: CNC)Q2 2023 Earnings CallJul 28, 2023, 8:30 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock

Shares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock

Shares of Genelux (NASDAQ: GNLX) were up 14.8% for the week, as of 9:30 a.m. ET Friday, according to data provided by S&P Global Market Intelligence. The clinical-stage biotech company's stock

In June, UnitedHealth Group (NYSE: UNH) alerted investors that its costs were creeping up due to increasing demand for surgeries. That led to a decline in the share price heading into the company's

In June, UnitedHealth Group (NYSE: UNH) alerted investors that its costs were creeping up due to increasing demand for surgeries. That led to a decline in the share price heading into the company's

With a market cap of $472 billion and tens of millions of people covered under its plans, UnitedHealth Group (NYSE: UNH) is the undisputed king of health insurance stocks. But over the last 12

With a market cap of $472 billion and tens of millions of people covered under its plans, UnitedHealth Group (NYSE: UNH) is the undisputed king of health insurance stocks. But over the last 12

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q2 2023 Earnings CallJul 27, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q2 2023 Earnings CallJul 27, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Biotech stocks are famously volatile, and investors needed to look no further than the performance of Novocure's (NASDAQ: NVCR) shares on Thursday for proof. The company's share price cratered by

Image source: The Motley Fool.

AbbVie (NYSE: ABBV)Q2 2023 Earnings CallJul 27, 2023, 9:00 a.m. ET

Liz Shea

Continue reading

Source Fool.com